Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Phase 3 data expected in the second half of 2024
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The company has raised US$4.5 million in funding for its AI operating system
European operations' revenue grew 58.4% to Rs 599.7 crore
Lack of technology transfer stands out as a formidable barrier
This product will be manufactured at Lupin’s Pithampur facility in India
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Subscribe To Our Newsletter & Stay Updated
